Uncategorised - European Medical Journal

Unravelling HER2+ Breast Cancer

A highly engaging infographic providing information on the incidence, diagnosis and treatment options for HER2+ breast cancer. It touches…

The latest edition of EMJ Oncology

The latest edition of EMJ Oncology is out now, featuring coverage from the 2024 European Society for Medical Oncology Congress…

Review of the European Society for Medical Oncology (ESMO) Congress 2024

KNOWN for its research excellence in the fields of oncology, bionanomedicine, and cardiovascular disease, Barcelona, Spain, provided the…

ER+/HER2- Metastatic Breast Cancer – Treatment after ET + CDK4/6i

Over 70% of breast cancers are ER+/HER2-, for which the backbone of treatment is ET.1-3 Advanced breast cancer (aBC) can be considered to…

Predisposition, Clinical Characteristics and Management of Immune Checkpoint Inhibitor-Induced Nephritis

Immune checkpoint inhibitors (ICI) use can lead to an array of immune-related adverse events (irAE). Nephritis is considered to be…

Advances in Treatment for Oestrogen Receptor-Positive Breast Cancer

THIS YEAR the European Society for Medical Oncology (ESMO) Congress was hosted in Barcelona, Spain from 13th–17th September. Among the…

Cancer Vaccines

An insightful infographic summarising the latest in cancer vaccines research. Information provided summarises the prevalence of certain…

Patient-Centred Therapies for mNSCLC

The metastatic non-small cell lung cancer (mNSCLC) treatment landscape has vastly expanded over the past two decades as a result of…

ESMO 2024 Abstract Highlights

The following abstracts showcase the top cutting-edge research presented at the European Society for Medical Oncology (ESMO) Congress 2024…

Immunotherapy in Endometrial Cancer: What Should We Know?

IMMUNOTHERAPY with chemotherapy is emerging as a new standard first-line treatment in advanced endometrial cancer (EC). In an insightful…